High materiality7/10
BlossomHill Therapeutics price target raised to $40 from $36 at Leerink Partners
Why it may matterVerify against the original reporting
Upside implied by target raise.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Leerink Partners raises BLSM price target to $40; current price ~ $26.19; implies substantial upside.
- Leerink raises BLSM PT to $40; current ~ $26.19.
Key facts
- 01
Target: $40
- 02
Posted price: $26.19
- 03
Analyst firm: Leerink Partners
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.